Journal
SCIENCE
Volume 320, Issue 5874, Pages 373-376Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.1154315
Keywords
-
Categories
Funding
- NIGMS NIH HHS [R01 GM060938-09, GM60938, R01 GM060938, R01 GM054045, R01 GM054045-11] Funding Source: Medline
Ask authors/readers for more resources
It is well established that high doses of monomeric immunoglobulin G ( IgG) purified from pooled human plasma [ intravenous immunoglobulin ( IVIG)] confer anti- inflammatory activity in a variety of autoimmune settings. However, exactly how those effects are mediated is not clear because of the heterogeneity of IVIG. Recent studies have demonstrated that the anti- inflammatory activity of IgG is completely dependent on sialylation of the N- linked glycan of the IgG Fc fragment. Here we determine the precise glycan requirements for this anti- inflammatory activity, allowing us to engineer an appropriate IgG1 Fc fragment, and thus generate a fully recombinant, sialylated IgG1 Fc with greatly enhanced potency. This therapeutic molecule precisely defines the biologically active component of IVIG and helps guide development of an IVIG replacement with improved activity and availability.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available